ALSO NOTED: Silenor positive in Phase III; BioSante wins FDA approval;and much more...

> A late stage trial of Somaxon's insomnia drug Silenor produced positive results for elderly patients with chronic pulmonary insomnia. Report

> BioSante has won FDA approval of Bio-E-Gel, which will be marketed under the name Elestrin for hot flashes. Release

> The FDA has approved SkyePharma's asthma spray Foradil Certihaler. Release

> Merck has won the latest trial over Vioxx, bringing its total score to eight wins and four losses. Report

> The Wall Street Journal examines the way investors deal with a biotech company's nasty trial surprises: dumping their stock and sending prices down 40 percent to 60 percent. Neurochem CEO Francesco Bellini says that investors need to learn to diversify. Article (sub. req.)

> NovaDel Pharma has agreed to sell 9.8 million shares for $14 million. Report

> MedImmune has completed the sale of CytoGam to ZLB Behring. Report

> How useful is animal testing for predicting human outcomes? A new report from the British Medical Journal attempts to answer that question. Report

And Finally…The big push to make sure there was plenty of flu vaccine available for the season has created a glut. And next year, manufacturers may respond by making less. Article

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.